North America and Europe Women's Health Market - Industry Trends and Forecast to 2031

List of Tables

Europe women's health market is expected to reach USD 5,384.03 million by 2031, from USD 3,280.54 million in 2023 growing at the CAGR of 6.7% in the forecast period of 2024 to 2031.

North America women's health market is expected to reach USD 11,108.64 million by 2031 from USD 5,841.61 million in 2023, growing at a CAGR of 9.3% in the forecast period of 2024 to 2031.

Market Segmentation

North America and Europe Women's Health Market, By Treatment (Drugs and Devices), Indication (Cancer, Reproductive Health, Urological Disorders, Hypothyroidism, Post-Menopausal Syndrome, and Others), Delivery Mode (Prescription and Over The Counter), Drug Type (Branded and Generic), Care Type (General Healthcare & Wellness, Pregnancy & Nursing Care, Pelvic & Uterine Healthcare, and Others), End User (Hospitals and Clinics, Gynecology Centers, Homecare Settings, Homecare Setting, Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, Online Sales, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe Women's Health Market Dynamics

Driver
Rising rates of chronic debilitating conditions among women
Restrain
Adverse effects associated with certain products
Opportunity
Growing awareness and acceptance of fertility treatments

Market Players

Some of the major players operating in the North America and Europe women's health market are:

Pfizer Inc.
Lilly
Novartis AG
AbbVie Inc.
GSK plc.
Abbott
Noven Pharmaceuticals, Inc.
Lupin
Vertical Pharmaceuticals, LLC
Veru Inc.

1 INTRODUCTION 31

1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 33

2 MARKET SEGMENTATION 37

2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.6 MULTIVARIATE MODELLING 45
2.7 MARKET APPLICATION COVERAGE GRID 46
2.8 PRODUCT LIFELINE CURVE 47
2.9 DBMR MARKET POSITION GRID 48
2.10 VENDOR SHARE ANALYSIS 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51

3 EXECUTIVE SUMMARY 52

4 PREMIUM INSIGHTS 55

4.1 PESTEL ANALYSIS 57
4.2 PORTER'S FIVE FORCES 58
4.3 INDUSTRY INSIGHTS 59
- 4.3.1 DRUG TREATMENT RATE IN MATURED MARKETS 59
- 4.3.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 59
- 4.3.3 PATIENT FLOW DIAGRAMS 59
- 4.3.4 KEY PRICING STRATEGIES 60
- 4.3.5 KEY ENROLLMENT STRATEGIES 60
4.4 PIPELINE ANALYSIS 63
4.5 PATENT DATA ANALYSIS 67

5 MARKET OVERVIEW 71

5.1 DRIVERS 73
- 5.1.1 RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN 73
- 5.1.2 INNOVATIVE TECHNOLOGIES BEING DEVELOPED AS AN AFTERMATH OF R&D ACTIVITIES 73
- 5.1.3 GOVERNMENT INITIATIVES TO IMPROVE OVERALL HEALTH AND WELLBEING 74
- 5.1.4 CHANGING LIFESTYLES AND ENVIRONMENTAL FACTORS IMPACTING HEALTH 75
5.2 RESTRAINTS 76
- 5.2.1 ADVERSE EFFECTS ASSOCIATED WITH CERTAIN PRODUCTS 76
- 5.2.2 STRICT REGULATIONS IMPOSED BY THE REGULATORY AGENCIES 76
5.3 OPPORTUNITIES 77
- 5.3.1 INCREASING RECOGNITION FOR MENTAL HEALTH 77
- 5.3.2 GROWING AWARENESS AND ACCEPTANCE OF FERTILITY TREATMENTS 78
- 5.3.3 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES 79
5.4 CHALLENGES 80
- 5.4.1 ENVIRONMENTAL EXPOSURE IMPACTING REPRODUCTIVE HEALTH 80
- 5.4.2 HIGH MATERNAL MORTALITY AND MORBIDITY 81

6 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT 82

6.1 OVERVIEW 83
6.2 DRUGS 89
6.3 DEVICE 98

7 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY INDICATION 100

7.1 OVERVIEW 101
7.2 CANCER 108
7.3 REPRODUCTIVE HEALTH 109
7.4 UROLOGICAL DISORDERS 110
7.5 HYPOTHYROIDISM 110
7.6 POST-MENOPAUSAL SYNDROME 110
7.7 OTHERS 111

8 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY CARE TYPE 112

8.1 OVERVIEW 113
8.2 GENERAL HEALTHCARE & WELLNESS 120
8.3 PREGNANCY & NURSING CARE 121
8.4 PELVIC & UTERINE HEALTHCARE 122
8.5 OTHERS 122

9 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE 123

9.1 OVERVIEW 124
9.2 BRANDED 130
9.3 GENERIC 130

10 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE 131

10.1 OVERVIEW 132
10.2 PRESCRIPTION 138
10.3 OVER THE COUNTER 138

11 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY END USER 139

11.1 OVERVIEW 140
11.2 HOSPITALS AND CLINICS 146
11.3 GYNECOLOGY CENTERS 146
11.4 HOMECARE SETTING 147
11.5 RESEARCH INSTITUTES 147
11.6 OTHERS 147

12 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL 148

12.1 OVERVIEW 149
12.2 DIRECT TENDERS 155
12.3 RETAIL SALES 155
12.4 ONLINE SALES 155
12.5 OTHERS 156

13 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY REGION 157

13.1 NORTH AMERICA 157
- 13.1.1 U.S. 160
- 13.1.2 CANADA 169
- 13.1.3 MEXICO 177
13.2 EUROPE 185
- 13.2.1 GERMANY 188
- 13.2.2 FRANCE 196
- 13.2.3 U.K. 205
- 13.2.4 ITALY 213
- 13.2.5 RUSSIA 221
- 13.2.6 SPAIN 229
- 13.2.7 TURKEY 237
- 13.2.8 NETHERLANDS 245
- 13.2.9 SWITZERLAND 253
- 13.2.10 BELGIUM 261
- 13.2.11 REST OF EUROPE 269

14 NORTH AMERICA AND EUROPE WOMEN HEALTH MARKET: COMPANY LANDSCAPE 270

14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 270
14.2 COMPANY SHARE ANALYSIS: EUROPE 271

15 SWOT ANALYSIS 272

16 COMPANY PROFILE 273

16.1 ABBOTT 273
- 16.1.1 COMPANY SNAPSHOT 273
- 16.1.2 REVENUE ANALYSIS 273
- 16.1.3 PRODUCT PORTFOLIO 274
- 16.1.4 RECENT DEVELOPMENT 274
16.2 ABBVIE INC. 275
- 16.2.1 COMPANY SNAPSHOT 275
- 16.2.2 REVENUE ANALYSIS 275
- 16.2.3 PRODUCT PORTFOLIO 276
- 16.2.4 RECENT DEVELOPMENT 276
16.3 GSK PLC. 277
- 16.3.1 COMPANY SNAPSHOT 277
- 16.3.2 REVENUE ANALYSIS 277
- 16.3.3 PRODUCT PORTFOLIO 278
- 16.3.4 RECENT DEVELOPMENT 278
16.4 LILLY 279
- 16.4.1 COMPANY SNAPSHOT 279
- 16.4.2 REVENUE ANALYSIS 279
- 16.4.3 PRODUCT PORTFOLIO 280
- 16.4.4 RECENT DEVELOPMENT 280
16.5 LUPIN 281
- 16.5.1 COMPANY SNAPSHOT 281
- 16.5.2 REVENUE ANALYSIS 281
- 16.5.3 PRODUCT PORTFOLIO 282
- 16.5.4 RECENT DEVELOPMENT 282
16.6 NOVARTIS AG 283
- 16.6.1 COMPANY SNAPSHOT 283
- 16.6.2 REVENUE ANALYSIS 283
- 16.6.3 PRODUCT PORTFOLIO 284
- 16.6.4 RECENT DEVELOPMENT 284
16.7 NOVEN PHARMACEUTICALS, INC. 285
- 16.7.1 COMPANY SNAPSHOT 285
- 16.7.2 PRODUCT PORTFOLIO 285
- 16.7.3 RECENT DEVELOPMENT 286
16.8 PFIZER INC. 287
- 16.8.1 COMPANY SNAPSHOT 287
- 16.8.2 REVENUE ANALYSIS 287
- 16.8.3 PRODUCT PORTFOLIO 288
- 16.8.4 RECENT DEVELOPMENT 288
16.9 VERTICAL PHARMACEUTICALS, LLC 289
- 16.9.1 COMPANY SNAPSHOT 289
- 16.9.2 PRODUCT PORTFOLIO 289
- 16.9.3 RECENT DEVELOPMENT 289
16.10 VERU INC. 290
- 16.10.1 COMPANY SNAPSHOT 290
- 16.10.2 REVENUE ANALYSIS 290
- 16.10.3 PRODUCT PORTFOLIO 291
- 16.10.4 RECENT DEVELOPMENT 291

17 QUESTIONNAIRE 292

18 RELATED REPORTS 295

LIST OF TABLES

TABLE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DEVICES 63
TABLE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DRUGS 66
TABLE 3 PATENT DATA (1/4) 67
TABLE 4 PATENT DATA (2/4) 67
TABLE 5 PATENT DATA (3/4) 68
TABLE 6 PATENT DATA (4/4) 69
TABLE 7 NORTH AMERICA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 89
TABLE 8 EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 89
TABLE 9 NORTH AMERICA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 89
TABLE 10 EUROPE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 89
TABLE 11 NORTH AMERICA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
TABLE 12 EUROPE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
TABLE 13 NORTH AMERICA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
TABLE 14 EUROPE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 15 NORTH AMERICA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 16 EUROPE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 91
TABLE 17 NORTH AMERICA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION 92
TABLE 18 EUROPE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
TABLE 19 NORTH AMERICA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
TABLE 20 EUROPE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 21 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 22 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 93
TABLE 23 NORTH AMERICA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
TABLE 24 EUROPE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
TABLE 25 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
TABLE 26 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 27 NORTH AMERICA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 28 EUROPE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 95
TABLE 29 NORTH AMERICA INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
TABLE 30 EUROPE INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
TABLE 31 NORTH AMERICA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
TABLE 32 EUROPE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
TABLE 33 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 97
TABLE 34 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
TABLE 35 NORTH AMERICA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
TABLE 36 EUROPE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
TABLE 37 NORTH AMERICA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 99
TABLE 38 EUROPE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 99
TABLE 39 NORTH AMERICA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 107
TABLE 40 EUROPE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 107
TABLE 41 NORTH AMERICA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 108
TABLE 42 EUROPE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 108
TABLE 43 NORTH AMERICA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 109
TABLE 44 EUROPE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 109
TABLE 45 NORTH AMERICA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 110
TABLE 46 EUROPE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 110
TABLE 47 NORTH AMERICA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
TABLE 48 EUROPE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 111
TABLE 49 NORTH AMERICA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 119
TABLE 50 EUROPE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 119
TABLE 51 NORTH AMERICA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 120
TABLE 52 EUROPE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 120
TABLE 53 NORTH AMERICA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
TABLE 54 EUROPE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 121
TABLE 55 NORTH AMERICA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 122
TABLE 56 EUROPE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 122
TABLE 57 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 130
TABLE 58 EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 130
TABLE 59 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 138
TABLE 60 EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 138
TABLE 61 NORTH AMERICA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 146
TABLE 62 EUROPE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 146
TABLE 63 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 155
TABLE 64 EUROPE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 155
TABLE 65 NORTH AMERICA WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 159
TABLE 66 U.S. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 160
TABLE 67 U.S. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
TABLE 68 U.S. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
TABLE 69 U.S. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 160
TABLE 70 U.S. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 71 U.S. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 72 U.S. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 73 U.S. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 161
TABLE 74 U.S. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
TABLE 75 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
TABLE 76 U.S. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 162
TABLE 77 U.S. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 163
TABLE 78 U.S. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 163
TABLE 79 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 163
TABLE 80 U.S. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 164
TABLE 81 U.S. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 164
TABLE 82 U.S. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 164
TABLE 83 U.S. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 164
TABLE 84 U.S. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
TABLE 85 U.S. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
TABLE 86 U.S. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 165
TABLE 87 U.S. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 166
TABLE 88 U.S. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 166
TABLE 89 U.S. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 166
TABLE 90 U.S. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 166
TABLE 91 U.S. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
TABLE 92 U.S. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 167
TABLE 93 U.S. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 167
TABLE 94 U.S. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 168
TABLE 95 CANADA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 169
TABLE 96 CANADA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
TABLE 97 CANADA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
TABLE 98 CANADA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 169
TABLE 99 CANADA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 100 CANADA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 101 CANADA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 102 CANADA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 170
TABLE 103 CANADA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
TABLE 104 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
TABLE 105 CANADA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 171
TABLE 106 CANADA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 172
TABLE 107 CANADA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 172
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 172
TABLE 109 CANADA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
TABLE 110 CANADA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
TABLE 111 CANADA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 173
TABLE 112 CANADA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 173
TABLE 113 CANADA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
TABLE 114 CANADA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
TABLE 115 CANADA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 174
TABLE 116 CANADA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 175
TABLE 117 CANADA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 175
TABLE 118 CANADA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 175
TABLE 119 CANADA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 175
TABLE 120 CANADA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 176
TABLE 121 CANADA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 176
TABLE 122 CANADA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 176
TABLE 123 CANADA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 176
TABLE 124 MEXICO WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 177
TABLE 125 MEXICO DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
TABLE 126 MEXICO HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
TABLE 127 MEXICO ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 177
TABLE 128 MEXICO PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
TABLE 129 MEXICO COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
TABLE 130 MEXICO GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
TABLE 131 MEXICO GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 178
TABLE 132 MEXICO LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 179
TABLE 133 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 179
TABLE 134 MEXICO NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 179
TABLE 135 MEXICO INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 180
TABLE 136 MEXICO AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 180
TABLE 137 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 180
TABLE 138 MEXICO DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 181
TABLE 139 MEXICO INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 181
TABLE 140 MEXICO WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 181
TABLE 141 MEXICO CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 181
TABLE 142 MEXICO REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 182
TABLE 143 MEXICO UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 182
TABLE 144 MEXICO OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 182
TABLE 145 MEXICO WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 183
TABLE 146 MEXICO WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 183
TABLE 147 MEXICO WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 183
TABLE 148 MEXICO GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 183
TABLE 149 MEXICO PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 184
TABLE 150 MEXICO PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 184
TABLE 151 MEXICO WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 184
TABLE 152 MEXICO WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 184
TABLE 153 EUROPE WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 187
TABLE 154 GERMANY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 188
TABLE 155 GERMANY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
TABLE 156 GERMANY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
TABLE 157 GERMANY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 188
TABLE 158 GERMANY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 189
TABLE 159 GERMANY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 189
TABLE 160 GERMANY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 189
TABLE 161 GERMANY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 189
TABLE 162 GERMANY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
TABLE 163 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
TABLE 164 GERMANY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 190
TABLE 165 GERMANY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
TABLE 166 GERMANY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
TABLE 167 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 191
TABLE 168 GERMANY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 192
TABLE 169 GERMANY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 192
TABLE 170 GERMANY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 192
TABLE 171 GERMANY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 192
TABLE 172 GERMANY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 193
TABLE 173 GERMANY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 193
TABLE 174 GERMANY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 193
TABLE 175 GERMANY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 194
TABLE 176 GERMANY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 194
TABLE 177 GERMANY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 194
TABLE 178 GERMANY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 194
TABLE 179 GERMANY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 195
TABLE 180 GERMANY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 195
TABLE 181 GERMANY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 195
TABLE 182 GERMANY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 195
TABLE 183 FRANCE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 196
TABLE 184 FRANCE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 196
TABLE 185 FRANCE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 196
TABLE 186 FRANCE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 196
TABLE 187 FRANCE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 188 FRANCE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 189 FRANCE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 190 FRANCE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 197
TABLE 191 FRANCE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
TABLE 192 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
TABLE 193 FRANCE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 198
TABLE 194 FRANCE INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
TABLE 195 FRANCE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
TABLE 196 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 199
TABLE 197 FRANCE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 200
TABLE 198 FRANCE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 200
TABLE 199 FRANCE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 200
TABLE 200 FRANCE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 200
TABLE 201 FRANCE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 201
TABLE 202 FRANCE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 201
TABLE 203 FRANCE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 201
TABLE 204 FRANCE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 202
TABLE 205 FRANCE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 202
TABLE 206 FRANCE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 202
TABLE 207 FRANCE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 202
TABLE 208 FRANCE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 203
TABLE 209 FRANCE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 203
TABLE 210 FRANCE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 203
TABLE 211 FRANCE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 204
TABLE 212 U.K. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 205
TABLE 213 U.K. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 214 U.K. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 215 U.K. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 205
TABLE 216 U.K. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 217 U.K. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 218 U.K. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 219 U.K. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 206
TABLE 220 U.K. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
TABLE 221 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
TABLE 222 U.K. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 207
TABLE 223 U.K. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
TABLE 224 U.K. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
TABLE 225 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 208
TABLE 226 U.K. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 209
TABLE 227 U.K. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 209
TABLE 228 U.K. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 209
TABLE 229 U.K. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 209
TABLE 230 U.K. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 210
TABLE 231 U.K. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 210
TABLE 232 U.K. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 210
TABLE 233 U.K. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 211
TABLE 234 U.K. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 211
TABLE 235 U.K. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 211
TABLE 236 U.K. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 211
TABLE 237 U.K. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 212
TABLE 238 U.K. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 212
TABLE 239 U.K. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 212
TABLE 240 U.K. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 212
TABLE 241 ITALY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 213
TABLE 242 ITALY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 243 ITALY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 244 ITALY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 213
TABLE 245 ITALY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 246 ITALY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 247 ITALY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 248 ITALY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 214
TABLE 249 ITALY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
TABLE 250 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
TABLE 251 ITALY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 215
TABLE 252 ITALY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
TABLE 253 ITALY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
TABLE 254 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 216
TABLE 255 ITALY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 217
TABLE 256 ITALY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 217
TABLE 257 ITALY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 217
TABLE 258 ITALY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 217
TABLE 259 ITALY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 218
TABLE 260 ITALY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 218
TABLE 261 ITALY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 218
TABLE 262 ITALY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 219
TABLE 263 ITALY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 219
TABLE 264 ITALY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 219
TABLE 265 ITALY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 219
TABLE 266 ITALY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 220
TABLE 267 ITALY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 220
TABLE 268 ITALY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 220
TABLE 269 ITALY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 220
TABLE 270 RUSSIA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 221
TABLE 271 RUSSIA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 272 RUSSIA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 273 RUSSIA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 221
TABLE 274 RUSSIA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 275 RUSSIA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 276 RUSSIA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 222
TABLE 278 RUSSIA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
TABLE 279 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
TABLE 280 RUSSIA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 223
TABLE 281 RUSSIA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
TABLE 282 RUSSIA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
TABLE 283 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 224
TABLE 284 RUSSIA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 225
TABLE 285 RUSSIA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 225
TABLE 286 RUSSIA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 225
TABLE 287 RUSSIA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 225
TABLE 288 RUSSIA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 226
TABLE 289 RUSSIA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 226
TABLE 290 RUSSIA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 226
TABLE 291 RUSSIA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 227
TABLE 292 RUSSIA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 227
TABLE 293 RUSSIA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 227
TABLE 294 RUSSIA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 227
TABLE 295 RUSSIA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 228
TABLE 296 RUSSIA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 228
TABLE 297 RUSSIA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 228
TABLE 298 RUSSIA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 228
TABLE 299 SPAIN WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 229
TABLE 300 SPAIN DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 229
TABLE 301 SPAIN HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 229
TABLE 302 SPAIN ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 229
TABLE 303 SPAIN PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 304 SPAIN COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 305 SPAIN GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 306 SPAIN GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 230
TABLE 307 SPAIN LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
TABLE 308 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
TABLE 309 SPAIN NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 231
TABLE 310 SPAIN INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 232
TABLE 311 SPAIN AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 232
TABLE 312 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 232
TABLE 313 SPAIN DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 233
TABLE 314 SPAIN INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 233
TABLE 315 SPAIN WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 233
TABLE 316 SPAIN CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 233
TABLE 317 SPAIN REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 234
TABLE 318 SPAIN UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 234
TABLE 319 SPAIN OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 234
TABLE 320 SPAIN WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 235
TABLE 321 SPAIN WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 235
TABLE 322 SPAIN WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 235
TABLE 323 SPAIN GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 235
TABLE 324 SPAIN PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 236
TABLE 325 SPAIN PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 236
TABLE 326 SPAIN WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 236
TABLE 327 SPAIN WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 236
TABLE 328 TURKEY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 237
TABLE 329 TURKEY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 237
TABLE 330 TURKEY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 237
TABLE 331 TURKEY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 237
TABLE 332 TURKEY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 333 TURKEY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 334 TURKEY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 335 TURKEY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 238
TABLE 336 TURKEY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 239
TABLE 337 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 239
TABLE 338 TURKEY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 239
TABLE 339 TURKEY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 240
TABLE 340 TURKEY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 240
TABLE 341 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 240
TABLE 342 TURKEY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 241
TABLE 343 TURKEY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 241
TABLE 344 TURKEY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 241
TABLE 345 TURKEY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 241
TABLE 346 TURKEY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 242
TABLE 347 TURKEY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 242
TABLE 348 TURKEY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 242
TABLE 349 TURKEY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 243
TABLE 350 TURKEY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 243
TABLE 351 TURKEY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 243
TABLE 352 TURKEY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 243
TABLE 353 TURKEY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 244
TABLE 354 TURKEY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 244
TABLE 355 TURKEY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 244
TABLE 356 TURKEY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 244
TABLE 357 NETHERLANDS WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 245
TABLE 358 NETHERLANDS DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 245
TABLE 359 NETHERLANDS HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 245
TABLE 360 NETHERLANDS ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 245
TABLE 361 NETHERLANDS PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 362 NETHERLANDS COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 363 NETHERLANDS GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 364 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 246
TABLE 365 NETHERLANDS LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 247
TABLE 366 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 247
TABLE 367 NETHERLANDS NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 247
TABLE 368 NETHERLANDS INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 248
TABLE 369 NETHERLANDS AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 248
TABLE 370 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 248
TABLE 371 NETHERLANDS DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 249
TABLE 372 NETHERLANDS INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 249
TABLE 373 NETHERLANDS WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 249
TABLE 374 NETHERLANDS CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 249
TABLE 375 NETHERLANDS REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 250
TABLE 376 NETHERLANDS UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 250
TABLE 377 NETHERLANDS OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 250
TABLE 378 NETHERLANDS WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 251
TABLE 379 NETHERLANDS WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 251
TABLE 380 NETHERLANDS WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 251
TABLE 381 NETHERLANDS GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 251
TABLE 382 NETHERLANDS PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 252
TABLE 383 NETHERLANDS PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 252
TABLE 384 NETHERLANDS WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 252
TABLE 385 NETHERLANDS WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 252
TABLE 386 SWITZERLAND WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 253
TABLE 387 SWITZERLAND DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 253
TABLE 388 SWITZERLAND HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 253
TABLE 389 SWITZERLAND ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 253
TABLE 390 SWITZERLAND PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 391 SWITZERLAND COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 392 SWITZERLAND GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 393 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 254
TABLE 394 SWITZERLAND LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 255
TABLE 395 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 255
TABLE 396 SWITZERLAND NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 255
TABLE 397 SWITZERLAND INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 256
TABLE 398 SWITZERLAND AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 256
TABLE 399 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 256
TABLE 400 SWITZERLAND DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 257
TABLE 401 SWITZERLAND INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 257
TABLE 402 SWITZERLAND WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 257
TABLE 403 SWITZERLAND CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 257
TABLE 404 SWITZERLAND REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 258
TABLE 405 SWITZERLAND UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 258
TABLE 406 SWITZERLAND OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 258
TABLE 407 SWITZERLAND WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 259
TABLE 408 SWITZERLAND WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 259
TABLE 409 SWITZERLAND WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 259
TABLE 410 SWITZERLAND GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 259
TABLE 411 SWITZERLAND PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 260
TABLE 412 SWITZERLAND PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 260
TABLE 413 SWITZERLAND WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 260
TABLE 414 SWITZERLAND WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 260
TABLE 415 BELGIUM WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 261
TABLE 416 BELGIUM DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 261
TABLE 417 BELGIUM HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 261
TABLE 418 BELGIUM ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 261
TABLE 419 BELGIUM PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 262
TABLE 420 BELGIUM COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 262
TABLE 421 BELGIUM GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 262
TABLE 422 BELGIUM GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 262
TABLE 423 BELGIUM LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 263
TABLE 424 BELGIUM GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 263
TABLE 425 BELGIUM NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 263
TABLE 426 BELGIUM INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 264
TABLE 427 BELGIUM AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 264
TABLE 428 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 264
TABLE 429 BELGIUM DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 265
TABLE 430 BELGIUM INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 265
TABLE 431 BELGIUM WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION) 265
TABLE 432 BELGIUM CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 265
TABLE 433 BELGIUM REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 266
TABLE 434 BELGIUM UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 266
TABLE 435 BELGIUM OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 266
TABLE 436 BELGIUM WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION) 267
TABLE 437 BELGIUM WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION) 267
TABLE 438 BELGIUM WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION) 267
TABLE 439 BELGIUM GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 267
TABLE 440 BELGIUM PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 268
TABLE 441 BELGIUM PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION) 268
TABLE 442 BELGIUM WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION) 268
TABLE 443 BELGIUM WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 268
TABLE 444 REST OF EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION) 269

LIST OF FIGURES

FIGURE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: SEGMENTATION 37
FIGURE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: DATA TRIANGULATION 40
FIGURE 3 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: DROC ANALYSIS 41
FIGURE 4 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 42
FIGURE 5 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: COMPANY RESEARCH ANALYSIS 43
FIGURE 6 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: INTERVIEW DEMOGRAPHICS 44
FIGURE 7 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: MARKET APPLICATION COVERAGE GRID 46
FIGURE 8 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: DBMR MARKET POSITION GRID 48
FIGURE 9 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: VENDOR SHARE ANALYSIS 50
FIGURE 10 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET: SEGMENTATION 54
FIGURE 11 THE RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET FROM 2024 TO 2031 55
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET IN 2024 AND 2031 56
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET 72
FIGURE 14 NORTH AMERICA WOMEN'S HEALTH MARKET: BY TREATMENT, 2023 83
FIGURE 15 NORTH AMERICA WOMEN'S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION) 84
FIGURE 16 NORTH AMERICA WOMEN'S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031) 84
FIGURE 17 NORTH AMERICA WOMEN'S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE 85
FIGURE 18 EUROPE WOMEN'S HEALTH MARKET: BY TREATMENT, 2023 86
FIGURE 19 EUROPE WOMEN'S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION) 87
FIGURE 20 EUROPE WOMEN'S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031) 87
FIGURE 21 EUROPE WOMEN'S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE 88
FIGURE 22 NORTH AMERICA WOMEN'S HEALTH MARKET: BY INDICATION, 2023 101
FIGURE 23 NORTH AMERICA WOMEN'S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION) 102
FIGURE 24 NORTH AMERICA WOMEN'S HEALTH MARKET: BY INDICATION, CAGR (2024-2031) 102
FIGURE 25 NORTH AMERICA WOMEN'S HEALTH MARKET: BY INDICATION, LIFELINE CURVE 103
FIGURE 26 EUROPE WOMEN'S HEALTH MARKET: BY INDICATION, 2023 104
FIGURE 27 EUROPE WOMEN'S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION) 105
FIGURE 28 EUROPE WOMEN'S HEALTH MARKET: BY INDICATION, CAGR (2024-2031) 105
FIGURE 29 EUROPE WOMEN'S HEALTH MARKET: BY INDICATION, LIFELINE CURVE 106
FIGURE 30 NORTH AMERICA WOMEN'S HEALTH MARKET: BY CARE TYPE, 2023 113
FIGURE 31 NORTH AMERICA WOMEN'S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION) 114
FIGURE 32 NORTH AMERICA WOMEN'S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031) 114
FIGURE 33 NORTH AMERICA WOMEN'S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE 115
FIGURE 34 EUROPE WOMEN'S HEALTH MARKET: BY CARE TYPE, 2023 116
FIGURE 35 EUROPE WOMEN'S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION) 117
FIGURE 36 EUROPE WOMEN'S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031) 117
FIGURE 37 EUROPE WOMEN'S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE 118
FIGURE 38 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DRUG TYPE, 2023 124
FIGURE 39 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION) 125
FIGURE 40 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031) 125
FIGURE 41 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE 126
FIGURE 42 EUROPE WOMEN'S HEALTH MARKET: BY DRUG TYPE, 2023 127
FIGURE 43 EUROPE WOMEN'S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION) 128
FIGURE 44 EUROPE WOMEN'S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031) 128
FIGURE 45 EUROPE WOMEN'S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE 129
FIGURE 46 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DELIVERY MODE, 2023 132
FIGURE 47 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION) 133
FIGURE 48 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031) 133
FIGURE 49 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE 134
FIGURE 50 EUROPE WOMEN'S HEALTH MARKET: BY DELIVERY MODE, 2023 135
FIGURE 51 EUROPE WOMEN'S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION) 136
FIGURE 52 EUROPE WOMEN'S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031) 136
FIGURE 53 EUROPE WOMEN'S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE 137
FIGURE 54 NORTH AMERICA WOMEN'S HEALTH MARKET: BY END USER, 2023 140
FIGURE 55 NORTH AMERICA WOMEN'S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION) 141
FIGURE 56 NORTH AMERICA WOMEN'S HEALTH MARKET: BY END USER, CAGR (2024-2031) 141
FIGURE 57 NORTH AMERICA WOMEN'S HEALTH MARKET: BY END USER, LIFELINE CURVE 142
FIGURE 58 EUROPE WOMEN'S HEALTH MARKET: BY END USER, 2023 143
FIGURE 59 EUROPE WOMEN'S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION) 144
FIGURE 60 EUROPE WOMEN'S HEALTH MARKET: BY END USER, CAGR (2024-2031) 144
FIGURE 61 EUROPE WOMEN'S HEALTH MARKET: BY END USER, LIFELINE CURVE 145
FIGURE 62 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023 149
FIGURE 63 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 150
FIGURE 64 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 150
FIGURE 65 NORTH AMERICA WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 151
FIGURE 66 EUROPE WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023 152
FIGURE 67 EUROPE WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 153
FIGURE 68 EUROPE WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 153
FIGURE 69 EUROPE WOMEN'S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 154
FIGURE 70 NORTH AMERICA WOMEN'S HEALTH MARKET: SNAPSHOT (2023) 157
FIGURE 71 EUROPE WOMEN'S HEALTH MARKET: SNAPSHOT (2023) 185
FIGURE 72 NORTH AMERICA WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%) 270
FIGURE 73 EUROPE WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%) 271